NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

CRISPR/CAS遺傳基因的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):產品&服務 (媒介為基礎的Cas、DNA自由Cas)、用途 (生物醫療、農業)、終端用戶、各地區

CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-based Cas, DNA-free Cas), By Application (Biomedical, Agriculture), By End Use, By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 1007488
出版日期 內容資訊 英文 220 Pages
商品交期: 2-10個工作天內
價格
CRISPR/CAS遺傳基因的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):產品&服務 (媒介為基礎的Cas、DNA自由Cas)、用途 (生物醫療、農業)、終端用戶、各地區 CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-based Cas, DNA-free Cas), By Application (Biomedical, Agriculture), By End Use, By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年05月14日內容資訊: 英文 220 Pages
簡介

全球CRISPR/CAS遺傳基因的市場規模在預測期間內預計以21.7%的年複合成長率發展,成長到2028年74億美元的規模。

這幾年,CRISPR遺傳基因編輯工具的引進及需求大幅度增加。CRISPR RNA 引導的核酸酶 Cas9 通過促進對包括人類基因組在內的多種真核基因組進行精確有效的基因修飾,推動了市場的發展,改善了遺傳學領域。該技術在各種醫療與其他非常規應用中的應用不斷增加。隨著越來越多的學術機構和生物技術公司致力於開發該技術的新商業應用,預計該基因編輯技術的專利競爭將加劇。此外,機器學習技術的實施在推動這種基因編輯技術方面顯示出巨大的潛力。

本報告提供全球CRISPR/CAS遺傳基因的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19)以及其他的市場影響因素分析,技術及專利趨勢,開發平台(管線)分析,市場規模的變化、預測,產品&服務、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 調查手法、調查範圍

第2章 摘要整理

第3章 市場可變因素、趨勢、展望

  • 市場趨勢、預測
  • 市場分類、範圍
  • 市場預測
  • 專利形勢
  • 普及、成長預測製圖
  • 對CRISPR技術的潛在威脅分析
  • 投資者的觀點
  • 用戶的觀點
  • 技術製圖
  • 關斷目標效果的分析用開發、創新
  • CRISPR技術:臨床部門的普及
  • COVID-19:影響分析

第4章 產業預測

  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會
    • 市場課題
  • 法律規章
  • 波特的五力分析
  • SWOT分析

第5章 競爭情形

  • 活用遺傳基因編輯技術的企業
  • 主要交易、策略性聯盟
  • 打入市場策略
  • 開發平台分析

第6章 市場預測、趨勢分析:各產品、服務

  • 產品
  • 服務

第7章 市場預測、趨勢分析:各用途

  • 生物醫療
  • 農業

第8章 市場預測、趨勢分析:各終端用戶

  • 生物科技、製藥企業
  • 學術機構、政府研究機關
  • CRO

第9章 市場預測、趨勢分析:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 企業簡介

  • CRISPR的主要創新者和研究的焦點
  • 策略性架構
  • 進入經營者的分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-375-1

CRISPR And Cas Genes Market Growth & Trends

The global CRISPR and cas genes market size is expected to reach USD 7.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 21.7% from 2021 to 2028. The adoption rate and demand for CRISPR gene editing tools have significantly increased in the past few years. CRISPR RNA-guided nuclease Cas9 has improved the genetics arena by facilitating precise and efficient genetic modification of diverse eukaryotic genomes, including human genomes, thereby driving the market.

The outbreak of COVID-19 shifted the focus of researchers towards the development of molecular diagnostic tools for COVID-19 based on this technology. For instance, in March 2021, researchers from Nanyang Technological University, Singapore developed a CRISPR-based COVID-19 test that delivers results in 30 minutes. This test detects the virus even after the mutation. This would encourage other players to leverage this opportunity.

Implementation of this technology in various medical and other non-conventional applications continues to increase. With a rising number of academic institutions and biotech companies working toward the development of new commercial applications of this technology, competition over patents for this gene-editing technology is expected to intensify. Furthermore, the implementation of machine-learning technologies exhibits great potential in advancing this gene-editing technology.

CRISPR And Cas Genes Market Report Highlights

The product segment accounted for the largest revenue share in 2020 due to the availability of a wide portfolio and increasing usage across several end-users

For instance, a large number of screening libraries are available for high-throughput gene editing studies, thereby driving the segment

Furthermore, the introduction of engineered enzymes along with the combination of different enzymes has attributed to the significant share of this segment

Technological advancements have resulted in a simplified genome engineering process. This, in turn, contributed to the higher adoption of this technology in cell line engineering

Biomedical applications are witnessing the highest penetration of this technology. Extensive research for human and non-human genomics has driven the segment

Biotechnology and pharmaceutical companies are estimated as the largest key end-users of the market

Reduced cost and time associated with genetic modification along with the availability of investments is anticipated to drive segment growth.

Also, the global COVID-19 pandemic has driven investment flow in the segment for the development of rapid CRISPR-based POC tests by biotechnology companies.

North America dominated the market owing to the presence of a strong research base that is engaged in the development as well as usage of this gene-editing tool.

Moreover, the U.S. exhibits a well-established market for gene-modified therapies that have positively influenced the adoption of molecular scissors in the region.

Asia Pacific is anticipated to witness the fastest CAGR throughout the forecast period.

China has a significant presence in this market and is actively engaged in exploring this space to develop novel therapies.

Collaborations between global and domestic players for the use of patented CRISPR tools supplemented the regional growth.

The key companies are focusing on collaboration and new product launches to sustain their position in the global market.

Table of Contents

Chapter 1 CRISPR & Cas Genes Market: Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Model
    • 1.3.1 Parent Market Study
    • 1.3.2 CRISPR and Cas genes market study
      • 1.3.2.1 Market study, by product & service
      • 1.3.2.2 Market study, by application
      • 1.3.2.3 Market study, by end-use
      • 1.3.2.4 Market study, by region
  • 1.4 Objectives
    • 1.4.1 Objective 1
    • 1.4.2 Objective 2

Chapter 2 CRISPR & Cas Genes Market: Executive Summary

  • 2.1 Market Snapshot, 2020 (USD Million)

Chapter 3 CRISPR & Cas Genes Market: Market Variables, Trends & Scope

  • 3.1 Market Trends & Outlook
  • 3.2 Market Segmentation & Scope
  • 3.3 Market Lineage outlook
    • 3.3.1 Parent market outlook
    • 3.3.2 Related/ancillary market outlook
  • 3.4 CRISPR and Cas Genes: Patent Landscape
    • 3.4.1 By end-use settings
    • 3.4.2 By variants of CRISPR enzymes
  • 3.5 Penetration and Growth Prospect Mapping, By Biomedical Applications, 2020
  • 3.6 Potential Threat Analysis to CRISPR Technology
    • 3.6.1 Variations in the CRISPR system
  • 3.7 Investors Perspective Analysis
  • 3.8 User Perspective Analysis
  • 3.9 Technology Mapping in CRISPR Genome Editing Workflow
  • 3.10 Developments and Innovations for Analysis of Off-Target Effects
  • 3.11 CRISPR Technologies: Clinical Penetration
    • 3.11.1 Human therapeutics
    • 3.11.2 Diagnostics
    • 3.11.3 Microbiome research and drug resistance
    • 3.11.4 Animal disease models
  • 3.12 COVID-19 Impact Analysis
    • 3.12.1 Short term impact
    • 3.12.2 Long term impact
    • 3.12.3 Challenge analysis
    • 3.12.4 Opportunity analysis

Chapter 4 CRISPR & Cas Genes Market: Industry Outlook

  • 4.1 Market Dynamics
    • 4.1.1 Market driver analysis
      • 4.1.1.1 Rising adoption in diverse fields of biotechnology
      • 4.1.1.1.1 Epigenetics
      • 4.1.1.1.2 Medicine
      • 4.1.1.1.3 Human germline editing
      • 4.1.1.1.4 Tool for qualitative and quantitative plant genome editing
      • 4.1.1.2 Technological advancements in CRISPR
      • 4.1.1.3 Introduction of anti-CRISPR protein
      • 4.1.1.4 Ongoing competition for crispr commercialization
    • 4.1.2 Market restraint analysis
      • 4.1.2.1 Off-target effects of crispr technology
      • 4.1.2.2 Intellectual property disputes pertaining to Cas
      • 4.1.2.3 Ethical concerns and implications with respect to human genome editing
    • 4.1.3 Market opportunity analysis
      • 4.1.3.1 Expanding gene & cell therapy area
      • 4.1.3.2 Government fund in genomic R&D
    • 4.1.4 Market challenge analysis
      • 4.1.4.1 Risks pertaining to the usage of genetically modified food
  • 4.2 Policy Making & Regulation for Genetic modification Using CRISPR
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Threat of new entrants: Moderate
    • 4.3.2 Competitive rivalry: High
    • 4.3.3 Threat of substitutes: Moderate
    • 4.3.4 Bargaining power of suppliers: Low
    • 4.3.5 Bargaining power of buyers: Moderate
  • 4.4 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
    • 4.4.1 Political & legal
    • 4.4.2 Economic
    • 4.4.3 Technological

Chapter 5 CRISPR & Cas Genes Market: Competitive Landscape

  • 5.1 Companies (Diagnostic & Drug Developers) Leveraging Gene Editing Technologies
  • 5.2 Major Deals & Strategic Alliances Analysis
  • 5.3 Market Entry Strategies
    • 5.3.1 CRISPR therapeutics: business translation
    • 5.3.2 CRISPR gene editing companies' toolboxes
  • 5.4 CRISPR and Cas Genes Market: Pipeline Analysis
    • 5.4.1 Editas Medicine
    • 5.4.2 Intellia Therapeutics, Inc.
    • 5.4.3 Crispr Therapeutics
    • 5.4.4 Caribou Biosciences, Inc.
    • 5.4.5 Egenesis
    • 5.4.6 Beam Therapeutics
    • 5.4.7 Ksq Therapeutics
    • 5.4.8 Cibus

Chapter 6 CRISPR & Cas Genes Market: Product & Service Business Analysis

  • 6.1 CRISPR and Cas Genes Market: Product & Service Movement Analysis
  • 6.2 Product
    • 6.2.1 Global CRISPR and Cas genes products market, 2017 - 2028 (USD Million)
    • 6.2.2 Kits & enzymes
      • 6.2.2.1 Global CRISPR and Cas genes kits and enzymes market, 2017 - 2028 (USD Million)
      • 6.2.2.2 Vector-based Cas9
      • 6.2.2.2.1 Global vector-based Cas9 market, 2017 - 2028 (USD Million)
      • 6.2.2.3 DNA-FREE CAS9
      • 6.2.2.3.1 GLOBAL DNA-free Cas9 market, 2017 - 2028 (USD Million)
    • 6.2.3 Libraries
      • 6.2.3.1 Global CRISPR and Cas genes libraries market, 2017 - 2028 (USD Million)
    • 6.2.4 Design Tools
      • 6.2.4.1 Global CRISPR and Cas genes design tool market, 2017 - 2028 (USD Million)
    • 6.2.5 Antibodies
      • 6.2.5.1 Global CRISPR and Cas genes antibodies market, 2017 - 2028 (USD Million)
    • 6.2.6 Others
      • 6.2.6.1 Global CRISPR and Cas genes market for other products, 2017 - 2028 (USD Million)
  • 6.3 Service
    • 6.3.1 Global CRISPR and Cas genes service market, 2017 - 2028 (USD Million)
    • 6.3.2 Cell line engineering
      • 6.3.2.1 Global cell engineering services market, 2017 - 2028 (USD Million)
    • 6.3.3 GRNA design
      • 6.3.3.1 Global GRNA design market, 2017 - 2028 (USD Million)
    • 6.3.4 Microbial gene editing
      • 6.3.4.1 Global microbial gene editing market, 2017 - 2028 (USD Million)
    • 6.3.5 DNA synthesis
      • 6.3.5.1 Global DNA synthesis market, 2017 - 2028 (USD Million)

Chapter 7 CRISPR & Cas Genes Market: Application Business Analysis

  • 7.1 CRISPR and Cas Genes Market: Application Movement Analysis
  • 7.2 Biomedical
    • 7.2.1 Global CRISPR and Cas genes market for biomedical, 2017 - 2028 (USD Million)
    • 7.2.2 Genome engineering
      • 7.2.2.1 Global CRISPR and Cas genes market for genome engineering, 2017 - 2028 (USD Million)
    • 7.2.3 Disease model studies
      • 7.2.3.1 Global CRISPR and Cas genes market for disease model studies, 2017 - 2028 (USD Million)
    • 7.2.4 Functional genomics
      • 7.2.4.1 GlobaL CRISPR and Cas genes market for functional genomics, 2017 - 2028 (USD Million)
    • 7.2.5 Epigenetics
      • 7.2.5.1 Global CRISPR and Cas genes market for epigenetics, 2017 - 2028 (USD Million)
    • 7.2.6 Others
      • 7.2.6.1 Global CRISPR and Cas genes market for other biomedical applications, 2017 - 2028 (USD Million)
  • 7.3 Agriculture
    • 7.3.1 Global CRISPR and Cas genes market for agriculture, 2017 - 2028 (USD Million)

Chapter 8 CRISPR & Cas Genes Market: End-Use Business Analysis

  • 8.1 CRISPR and Cas Genes Market: End-use Movement Analysis
  • 8.2. Biotechnology & pharmaceutical companies
    • 8.2.1 Global CRISPR and Cas genes market for biotechnology & pharmaceutical companies, 2017 - 2028 (USD Million)
  • 8.3 Academics & government research institutes
    • 8.3.1 Global CRISPR and Cas genes market for academics & government research institutes, 2017 - 2028 (USD Million)
  • 8.4 Contract Research Organizations (CROS)
    • 8.4.1 Global CRISPR and Cas genes market for CROS, 2017 - 2028 (USD Million)

Chapter 9 CRISPR & Cas Genes Market: Regional Business Analysis

  • 9.1 CRISPR and Cas Genes Market: Regional Movement Analysis, 2020 and 2028
  • 9.2 North America
    • 9.2.1 North America CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. CRISPR and Cas genes market estimates and forecast, by product & service 2017 - 2028 (USD Million)
      • 9.2.2.2 U.S. CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.2.2.3 U.S. CRISPR and Cas genes market estimates and forecast, 2017 - 2028, by end-use (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.2.3.2 Canada CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.2.3.3 Canada CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.3.2.2 Germany CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.3.2.3 Germany CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.3.3.2 U.K. CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.3.3.3 U.K. CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.3.4 France
      • 9.3.4.1 France CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.3.4.2 France CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.3.4.3 France CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.3.5 Itlay
      • 9.3.5.1 Italy CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.3.5.2 Italy CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.3.5.3 Italy CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.3.6 Spain
      • 9.3.6.1 Spain CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.3.6.2 Spain. CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.3.6.3 Spain CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.4.2.2 Japan CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.4.2.3 Japan CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.4.3.2 China CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.4.3.3 China CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.4.4 South Korea
      • 9.4.4.1 South Korea CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.4.4.2 South Korea CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.4.4.3 South Korea CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.4.5 India
      • 9.4.5.1 India CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.4.5.2 India CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.4.5.3 India CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.5.2.2 Brazil CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.5.2.3 Brazil CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 MexicoCRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.5.3.2 Mexico CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.5.3.3 Mexico CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
  • 9.6 Middle East & Africa (MEA)
    • 9.6.1 MEA CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.6.2.2 South Africa CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.6.2.3 South Africa CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Saudi Arabia CRISPR and Cas genes market estimates and forecast, by product & service, 2017 - 2028 (USD Million)
      • 9.6.3.2 Saudi Arabia CRISPR and Cas genes market estimates and forecast, by application, 2017 - 2028 (USD Million)
      • 9.6.3.3 Saudi Arabia CRISPR and Cas genes market estimates and forecast, by end-use, 2017 - 2028 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Top CRISPR Innovators and Their Research Focus
  • 10.2 Strategy Framework
  • 10.3 Market Participant Categorization
  • 10.4 Company Profiles
    • 10.4.1 AstraZeneca
      • 10.4.1.1 Company overview
      • 10.4.1.2 Financial performance
      • 10.4.1.3 Product benchmarking
      • 10.4.1.4 Strategic initiatives
    • 10.4.2 Addgene
      • 10.4.2.1 Company overview
      • 10.4.2.2 Financial performance
      • 10.4.2.3 Product benchmarking
    • 10.4.3 Caribou Biosciences, Inc.
      • 10.4.3.1 Company overview
      • 10.4.3.2 Financial performance
      • 10.4.3.3 Product benchmarking
      • 10.4.3.4 Strategic initiatives
    • 10.4.4 Cellectis
      • 10.4.4.1 Company overview
      • 10.4.4.2 Calyxt, Inc.
      • 10.4.4.3 Financial performance
      • 10.4.4.4 Product benchmarking
      • 10.4.4.5 Strategic initiatives
    • 10.4.5 CRISPRTherapeutics
      • 10.4.5.1 Company overview
      • 10.4.5.2 Financial performance
      • 10.4.5.3 Product benchmarking
      • 10.4.5.4 Strategic initiatives
    • 10.4.6 Editas Medicine, Inc.
      • 10.4.6.1 Company overview
      • 10.4.6.2 Financial performance
      • 10.4.6.3 Product benchmarking
      • 10.4.6.4 Strategic initiatives
    • 10.4.7 Egenesis
      • 10.4.7.1 Company overview
      • 10.4.7.2 Financial performance
      • 10.4.7.3 Product benchmarking
      • 10.4.7.4 Strategic initiatives
    • 10.4.8 F. Hoffmann-LA Roche Ltd.
      • 10.4.8.1 Company overview
      • 10.4.8.2 Mirus Bio LLC
      • 10.4.8.3 Financial performance
      • 10.4.8.4 Product benchmarking
    • 10.4.9 Horizon Discovery Group plc
      • 10.4.9.1 Company overview
      • 10.4.9.2 Dharmacon, Inc.
      • 10.4.9.3 Financial performance
      • 10.4.9.4 Product benchmarking
      • 10.4.9.5 Strategic initiatives
    • 10.4.10 Genscript
      • 10.4.10.1 Company overview
      • 10.4.10.2 Financial performance
      • 10.4.10.3 Product benchmarking
      • 10.4.10.4 Strategic initiatives
    • 10.4.11 Danaher Corporation
      • 10.4.11.1 Company overview
      • 10.4.11.2 Integrated DNA Technologies, Inc.
      • 10.4.11.3 Financial performance
      • 10.4.11.4 Product Benchmarking
      • 10.4.11.5 Strategic Initiatives
    • 10.4.12 Intellia Therapeutics, Inc.
      • 10.4.12.1 Company overview
      • 10.4.12.2 Financial performance
      • 10.4.12.3 Product benchmarking
      • 10.4.12.4 Strategic initiatives
    • 10.4.13 Lonza
      • 10.4.13.1Company overview
      • 10.4.13.2 Financial performance
      • 10.4.13.3 Product benchmarking
      • 10.4.13.4 Strategic initiatives
    • 10.4.14 Merck KGaA
      • 10.4.14.1 Company overview
      • 10.4.14.2 Sigma-Aldrich CO. LLC
      • 10.4.14.3 Financial performance
      • 10.4.14.4 Product benchmarking
      • 10.4.14.5 Strategic initiatives
    • 10.4.15 New England Biolabs
      • 10.4.15.1 Company overview
      • 10.4.15.2 Financial performance
      • 10.4.15.3 Product benchmarking
      • 10.4.15.4 Strategic initiatives
    • 10.4.16 Takara Bio, Inc.
      • 10.4.16.1 Company overview
      • 10.4.16.2 Financial performance
      • 10.4.16.3 Product benchmarking
      • 10.4.16.4 Strategic initiatives
    • 10.4.17 Thermo Fisher Scientific, Inc.
      • 10.4.17.1 Company overview
      • 10.4.17.2 Financial performance
      • 10.4.17.3 Product benchmarking
      • 10.4.17.4 Strategic initiatives
    • 10.4.18 Synthego
      • 10.4.18.1 Company overview
      • 10.4.18.2 Financial performance
      • 10.4.18.3 Product benchmarking
      • 10.4.18.4 Strategic initiatives
    • 10.4.19 Mammoth Biosciences
      • 10.4.19.1 Company overview
      • 10.4.19.2 Financial performance
      • 10.4.19.3 Product benchmarking
      • 10.4.19.4 Strategic initiatives
    • 10.4.20 Inscripta, Inc.
      • 10.4.20.1 Company overview
      • 10.4.20.2 Financial performance
      • 10.4.20.3 Product benchmarking
      • 10.4.20.4 Strategic initiatives
    • 10.4.21 Cibus
      • 10.4.21.1 Company overview
      • 10.4.21.2 Financial performance
      • 10.4.21.3 Product benchmarking
      • 10.4.21.4 Strategic initiatives
    • 10.4.22 Beam Therapeutics
      • 10.4.22.1 Company overview
      • 10.4.22.2 Financial performance
      • 10.4.22.3 Product benchmarking
      • 10.4.22.4 Strategic initiatives
    • 10.4.23 Plantedit
      • 10.4.23.1 Company overview
      • 10.4.23.2 Product benchmarking
      • 10.4.23.3 Strategic initiatives
    • 10.4.24 Vertex Pharmaceuticals Incorporated
      • 10.4.24.1 Company overview
      • 10.4.24.2 Financial performance
      • 10.4.24.3 Product benchmarking
      • 10.4.24.4 Strategic initiatives
    • 10.4.25 Hera Biolabs
      • 10.4.25.1 Company overview
      • 10.4.25.2 Product benchmarking
      • 10.4.25.3 Strategic initiatives
    • 10.4.26 Origene Technologies, Inc.
      • 10.4.26.1 Company overview
      • 10.4.26.2 Financial performance
      • 10.4.26.3 Product benchmarking
      • 10.4.26.4 Strategic initiatives
    • 10.4.27 Recombinetics, Inc.
      • 10.4.27.1 Company overview
      • 10.4.27.2 Financial performance
      • 10.4.27.3 Product benchmarking
      • 10.4.27.4 Strategic initiatives

List of Tables

  • TABLE 1 CRISPR-modified crops expected to be launched in the future
  • TABLE 2 Key collaborations between pharmaceutical and gene editing companies
  • TABLE 3 Key partnerships between pharmaceutical and gene editing companies
  • TABLE 4 Variations in the CRISPR system
  • TABLE 5 Methods to check genome editing on-target efficiency
  • TABLE 6 Unbiased methods to analyze off-target effects
  • TABLE 7 Collaboration between CAR-T companies & gene editing companies
  • TABLE 8 Comparison of natural Cas9 and Cas-like variants
  • TABLE 9 Pipeline analysis for Editas Medicine
  • TABLE 10 Pipeline analysis for Intellia Therapeutics, Inc.
  • TABLE 11 Pipeline analysis for CRISPR Therapeutics
  • TABLE 12 Pipeline analysis for Caribou Biosciences, Inc.
  • TABLE 13 Pipeline analysis for eGenesis
  • TABLE 14 Pipeline analysis for Beam Therapeutics
  • TABLE 15 Pipeline analysis for KSQ Therapeutics
  • TABLE 16 Pipeline analysis for Cibus
  • TABLE 17 Types of CRISPR screening libraries
  • TABLE 18 Types of CRISPR controls
  • TABLE 19 Types of cell engineering services
  • TABLE 20 North America CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 21 North America CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 22 North America CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 23 North America CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 24 North America CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 25 North America CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 26 North America CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 27 U.S. CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 28 U.S. CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 29 U.S. CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 30 U.S. CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 31 U.S. CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 32 U.S. CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 33 U.S. CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 34 Canada CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 35 Canada CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 36 Canada CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 37 Canada CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 38 Canada CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 39 Canada CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 40 Canada CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 41 Europe CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 42 Europe CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 43 Europe CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 44 Europe CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 45 Europe CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 46 Europe CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 47 Europe CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 48 Germany CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 49 Germany CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 50 Germany CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 51 Germany CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 52 Germany CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 53 Germany CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 54 Germany CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 55 U.K.CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 56 U.K.CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 57 U.K. CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 58 U.K. CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 59 U.K. CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 60 U.K.CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 61 U.K. CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 62 France CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 63 France CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 64 France CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 65 France CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 66 France CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 67 France CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 68 France CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 69 Italy CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 70 Italy CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 71 Italy CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 72 Italy CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 73 Italy CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 74 Italy CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 75 Italy CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 76 Spain CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 77 Spain CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 78 Spain CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 79 Spain CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 80 Spain CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 81 Spain CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 82 Spain CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 83 Asia Pacific CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 84 Asia Pacific CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 85 Asia Pacific CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 86 Asia Pacific CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 87 Asia Pacific CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 88 Asia Pacific CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 89 Asia Pacific CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 90 Japan CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 91 Japan CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 92 Japan CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 93 Japan CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 94 Japan CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 95 Japan CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 96 Japan CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 97 China CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 98 China CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 99 China CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 100 China CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 101 China CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 102 China CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 103 China CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 104 South Korea CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 105 South Korea CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 106 South Korea CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 107 South Korea CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 108 South Korea CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 109 South Korea CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 110 South Korea CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 111 India CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 112 IndiaCRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 113 India CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 114 India CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 115 India CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 116 India CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 117 India CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 118 Latin America CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 119 Latin America CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 120 Latin America CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 121 Latin America CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 122 Latin America CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 123 Latin America CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 124 Latin America CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 125 Brazil CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 126 Brazil CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 127 Brazil CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 128 Brazil CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 129 Brazil CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 130 Brazil CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 131 Brazil CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 132 Mexico CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 133 Mexico CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 134 Mexico CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 135 Mexico CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 136 Mexico CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 137 Mexico CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 138 Mexico CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 139 MEA CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 140 MEA CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 141 MEA CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 142 MEA CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 143 MEA CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 144 MEA CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 145 MEA CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 146 South Africa CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 147 South Africa CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 148 South Africa CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 149 South Africa CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 150 South Africa CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 151 South Africa CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 152 South Africa CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)
  • TABLE 153 Saudi Arabia CRISPR and Cas genes market, by product & service, 2017 - 2028 (USD Million)
  • TABLE 154 Saudi Arabia CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • TABLE 155 Saudi Arabia CRISPR and Cas genes kits & enzymes market, by type, 2017 - 2028 (USD Million)
  • TABLE 156 Saudi Arabia CRISPR and Cas genes service market, by type, 2017 - 2028 (USD Million)
  • TABLE 157 Saudi Arabia CRISPR and Cas genes market, by application, 2017 - 2028 (USD Million)
  • TABLE 158 Saudi Arabia CRISPR and Cas genes biomedical applications market, by type, 2017 - 2028 (USD Million)
  • TABLE 159 Saudi Arabia CRISPR and Cas genes market, by end-use, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Industry pyramid analysis
  • FIG. 4 Market formulation & validation
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 Primary research process
  • FIG. 8 Primary research validation
  • FIG. 9 Market model for CRISPR and Cas market
  • FIG. 10 Penetration of various technologies in the genome editing market
  • FIG. 11 QFD modeling for market share assessment, for product and service segment
  • FIG. 12 Analysis for the adoption and usage of products for CRISPR and Cas genes
  • FIG. 13 CRISPR studies for plant genome editing, by region
  • FIG. 14 CRISPR crops in the pipeline
  • FIG. 15 Survey respondents on the number of clones screened for identification of cells with desired edits
  • FIG. 16 Regional analysis for CRISPR patents
  • FIG. 17 Regional analysis for CRISPR clinical trials
  • FIG. 18 Regional analysis for CRISPR publications
  • FIG. 19 Multivariable analysis for the regional penetration of CRISPR and Cas genes
  • FIG. 20 Market snapshot, 2020(USD Million)
  • FIG. 21 Market trends & outlook
  • FIG. 22 CRISPR and Cas genes market segmentation
  • FIG. 23 CRISPR-related patents growth trend, U.S.
  • FIG. 24 Worldwide growth in CRISPR-related patents families
  • FIG. 25 Diversification of patent applications for CRISPR, by end-use, as of 2020
  • FIG. 26 Diversification of patent applications as per the CRISPR- enzymes, as of 2020
  • FIG. 27 Penetration and growth prospect mapping, by biomedical applications, 2020
  • FIG. 28 Comparison among prototype genome-editing techniques
  • FIG. 29 Consumer awareness of personalized medicine
  • FIG. 30 Technology penetration in CRISPR genome editing
  • FIG. 31 CRISPR and Cas genes market driver impact
  • FIG. 32 CRISPR and Cas genes market restraint impact
  • FIG. 33 Side effects of GM foods
  • FIG. 34 Key public players analysis
  • FIG. 35 Key private players analysis
  • FIG. 36 Types of major deals & strategic alliances
  • FIG. 37 CRISPR Therapeutics: Partnerships & alliances analysis
  • FIG. 38 Market entry strategies for small and mid-sized biopharma companies (End-user of gene editing technologies) and CRISPR technology developers
  • FIG. 39 CRISPR Therapeutics: Translation
  • FIG. 40 CRISPR gene editing companies' toolboxes
  • FIG. 41 Clinical strategy of operating companies
  • FIG. 42 CRISPR and Cas genes market: Product & service outlook and key takeaways
  • FIG. 43 CRISPR and Cas genes market: Product & service movement analysis
  • FIG. 44 Global CRISPR and Cas genes products market, by type, 2017 - 2028 (USD Million)
  • FIG. 45 Global CRISPR and Cas genes kits and enzymes market, by type, 2017 - 2028 (USD Million)
  • FIG. 46 Global vector-based Cas9 market, 2017 - 2028 (USD Million)
  • FIG. 47 Global DNA-free Cas9 market, 2017 - 2028 (USD Million)
  • FIG. 48 Global CRISPR and Cas genes libraries market, 2017 - 2028 (USD Million)
  • FIG. 49 Global CRISPR and Cas genes design tool market, 2017 - 2028 (USD Million)
  • FIG. 50 Applications of CRISPR-Cas9 antibodies
  • FIG. 51 Global CRISPR and Cas genes antibodies market, 2017 - 2028 (USD Million)
  • FIG. 52 Global CRISPR and Cas genes market for other products, 2017 - 2028 (USD Million)
  • FIG. 53 Global CRISPR and Cas genes service market, 2017 - 2028 (USD Million)
  • FIG. 54 Global cell engineering services market, 2017 - 2028 (USD Million)
  • FIG. 55 Global gRNA design market, 2017 - 2028 (USD Million)
  • FIG. 56 Global microbial gene editing market, 2017 - 2028 (USD Million)
  • FIG. 57 Global DNA synthesis market, 2017 - 2028 (USD Million)
  • FIG. 58 CRISPR and Cas genes market: Application outlook and key takeaways
  • FIG. 59 Potential applications of CRISPR technology for biomedical diagnostics
  • FIG. 60 CRISPR and Cas genes market: Application movement analysis
  • FIG. 61 Global CRISPR and Cas genes market for biomedical applications, 2017 - 2028 (USD Million)
  • FIG. 62 Global CRISPR and Cas genes market for genome engineering, 2017 - 2028 (USD Million)
  • FIG. 63 Global CRISPR and Cas genes market for disease model studies, 2017 - 2028 (USD Million)
  • FIG. 64 Global CRISPR and Cas genes market for functional genomics, 2017 - 2028 (USD Million)
  • FIG. 65 Global CRISPR and Cas genes market for epigenetics, 2017 - 2028 (USD Million)
  • FIG. 66 Global CRISPR and Cas genes market for other biomedical applications, 2017 - 2028 (USD Million)
  • FIG. 67 Global CRISPR and Cas genes market for agriculture, 2017 - 2028 (USD Million)
  • FIG. 68 CRISPR and Cas genes market: End-use outlook and key takeaways
  • FIG. 69 CRISPR and Cas genes market: End-use movement analysis
  • FIG. 70 Global CRISPR and Cas genes market for biotechnology & pharmaceutical companies, 2017 - 2028 (USD Million)
  • FIG. 71 Global CRISPR and Cas genes market for academics & government research institutes, 2017 - 2028 (USD Million)
  • FIG. 72 Global CRISPR and Cas genes market for CROs, 2017 - 2028 (USD Million)
  • FIG. 73 CRISPR and Cas genes market: Regional outlook and key takeaways
  • FIG. 74 CRISPR and Cas genes market: Regional movement analysis
  • FIG. 75 North America
  • FIG. 76 North America CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 77 U.S.
  • FIG. 78 U.S. CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 79 Canada
  • FIG. 80 Canada CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 81 Europe
  • FIG. 82 Europe CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 83 Germany
  • FIG. 84 Germany CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 85 U.K.
  • FIG. 86 U.K. CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 87 France
  • FIG. 88 France CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 89 Italy
  • FIG. 90 Italy CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 91 Spain
  • FIG. 92 Spain CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 93 Asia Pacific
  • FIG. 94 Asia Pacific CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 95 Japan
  • FIG. 96 Japan CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 97 China
  • FIG. 98 China CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 99 South Korea
  • FIG. 100 South Korea CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 101 India
  • FIG. 102 India CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 103 Latin America
  • FIG. 104 Latin America CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 105 Brazil
  • FIG. 106 Brazil CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 107 Mexico
  • FIG. 108 Mexico CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 109 MEA
  • FIG. 110 MEA CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 111 South Africa
  • FIG. 112 South Africa CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 113 Saudi Arabia
  • FIG. 114 Saudi Arabia CRISPR and Cas genes market estimates and forecast, 2017 - 2028 (USD Million)
  • FIG. 115 Top CRISPR innovators and their research focus
  • FIG. 116 Strategy framework
  • FIG. 117 Market participant categorization